12.1 Acute Coagulopathies: DIC, HIT & Anticoagulant Reversal

12.1 Acute Coagulopathies: DIC, HIT & Anticoagulant Reversal

Clinical Scenario: A 58-year-old male with septic shock from necrotizing fasciitis develops active oozing from central line and arterial catheter insertion sites, extensive purpura, and gross hematuria. Labs: platelets 34,000/mcL (baseline 195,000/mcL), PT 26.8 s (laboratory control 12 s; INR 2.4), aPTT 68 s, D-dimer >20 mcg/mL (ULN 0.5 mcg/mL), and fibrinogen 78 mg/dL. The acute care nurse practitioner must determine the diagnostic score and execute targeted hemostatic resuscitation.

Disseminated Intravascular Coagulation (DIC)

DIC is a systemic thrombohemorrhagic disorder initiated by excessive tissue factor (TF) expression on monocytes and injured endothelium under proinflammatory cytokines (TNF-alpha, IL-1, IL-6). Uncontrolled thrombin generation consumes natural anticoagulants (antithrombin III, protein C) and overwhelms microvascular fibrinolysis, leading to widespread microvascular fibrin deposition, tissue ischemia, and multiorgan dysfunction syndrome (MODS).

Ongoing consumptive coagulopathy depletes platelets, fibrinogen, and factors V and VIII. Fibrin turnover generates FDPs and D-dimers. Severe bleeding reflects consumption and, in some settings, excessive fibrinolysis; sepsis-associated DIC commonly has suppressed fibrinolysis:

• Acute (Overt) DIC: Rapid, decompensated consumption with severe thrombocytopenia, hypofibrinogenemia, prolonged PT/aPTT, and diffuse bleeding (puncture oozing, ecchymoses). Triggers include septic shock, polytrauma, crush injuries, and amniotic fluid embolism.
• Chronic (Non-Overt) DIC: Compensated state where hepatic synthesis and bone marrow production match consumption; coagulation parameters remain near normal. Presents with venous/arterial thrombosis; typical in advanced adenocarcinomas and aortic aneurysms.

ISTH Overt-DIC Score (2025 Update)

In a DIC-associated clinical disorder, a total score ≥5 is compatible with overt DIC; reassess daily. A score<5 is not diagnostic of overt DIC or of a separate nonovert syndrome; follow the clinical course and repeat testing.

Hemostatic Resuscitation in Acute DIC

1. Source Control: Aggressively eradicate underlying pathology (surgical debridement, broad-spectrum antibiotics, obstetrical evacuation).
2. Platelets: Transfuse to target $>50,000/\mu\text{L}$ for active hemorrhage or invasive procedures ($>20,000/\mu\text{L}$ if high bleeding risk; $10,000/\mu\text{L}$ prophylactic threshold).
3. Cryoprecipitate: 1–2 pools (10–20 units) to maintain fibrinogen $>100–150\text{ mg/dL}$ ($>150–200\text{ mg/dL}$ in obstetric/trauma hemorrhage).
4. Fresh Frozen Plasma (FFP): $15–30\text{ mL/kg}$ for bleeding with PT/INR $>1.5–2.0\times$ normal or prolonged aPTT.
5. Antifibrinolytics (TXA): Do not use routinely in septic DIC because inhibiting fibrinolysis can worsen thrombosis. Selected severe bleeding with dominant hyperfibrinolysis may warrant specialist-directed antifibrinolytic treatment; do not generalize that approach to all bleeding DIC.

Heparin-Induced Thrombocytopenia (HIT Type II)

HIT Type II is an immune-mediated disorder caused by IgG antibodies against platelet factor 4 (PF4)-heparin complexes. Binding of antibody complexes to platelet $\text{Fc}\gamma\text{RIIa}$ receptors causes intense platelet activation, thromboxane A2 release, and microparticle shedding, triggering massive thrombin generation. Paradoxically, HIT is a prothrombotic state ("white clot syndrome") with a 30-day thrombosis risk of 30%–50% (DVT, PE, arterial stroke, skin necrosis).

4Ts Pretest Probability Score

• Score 0–3 (Low): Continue heparin; no lab testing.
• Score 4–5 (Intermediate): Discontinue heparin; order PF4-ELISA; start non-heparin anticoagulant.
• Score 6–8 (High): Immediately stop all heparin; start non-heparin parenteral anticoagulant.

Diagnostic Testing & HIT Pharmacotherapy

• Assays: PF4 immunoassays are sensitive screening tests with assay-specific cutoffs. Interpret ELISA optical density alongside the 4Ts score; a positive screen alone does not confirm HIT. Obtain functional testing when indicated; a high 4Ts score with very strong ELISA positivity (e.g., OD >2.0) may suffice. The Serotonin Release Assay (SRA) is the gold-standard functional test measuring ${}^{14}\text{C}$-serotonin release ($>20\%$ at therapeutic heparin, suppressed at supratherapeutic levels).
• Immediate Steps: Discontinue all heparin sources (UFH, LMWH, catheter flushes). Do not give routine prophylactic platelet transfusions; reserve them for a compelling bleeding indication.
• Direct Thrombin Inhibitors (DTIs):
  • Argatroban: Hepatically cleared. Infuse at $2.0\text{ mcg/kg/min}$ (reduce to $0.5–1.2\text{ mcg/kg/min}$ in hepatic impairment or critical illness) to target aPTT $1.5–3.0\times$ baseline (50–70 seconds).
  • Bivalirudin: Cleared 20% renally and 80% proteolytically (half-life 25 min); preferred in PCI or combined organ dysfunction.
  • Fondaparinux: Subcutaneous factor Xa inhibitor; alternative in stable non-renal patients (CrCl $>30\text{ mL/min}$).
• Warfarin Prohibition: Warfarin is strictly contraindicated in acute HIT. Rapid protein C depletion before prothrombin declines produces an unopposed hypercoagulable state causing venous limb gangrene. Initiate warfarin only after platelet count recovers to $\ge 150,000/\mu\text{L}$, overlapping with a DTI for $\ge 5$ days until INR is therapeutic for $\ge 24$ hours.

Urgent Anticoagulant Reversal Protocols